Companion Diagnostic Approval

Guardant360 CDx has received FDA approval and is designated as a companion diagnostic linked to Boehringer Ingelheim’s investigational drug Hernexeos. Liquid biopsy detects tumor DNA in blood, enabling non‑invasive cancer diagnosis, and this approval accelerates patient selection.

Patient Benefits

By accurately identifying patients eligible for Hernexeos therapy, the companion diagnostic can improve treatment efficacy and reduce the risk of adverse events. Patients can receive appropriate therapy more quickly, which is also expected to lower overall cancer management costs.

Guardant Health Perspective

Guardant Health is strengthening its partnership‑based revenue model by linking the broadly applied Guardant360 CDx to a specific drug, and it opens opportunities for future collaborations with other pharmaceutical companies. The companion diagnostic market is projected to grow at a compound annual rate of 12% through the mid‑2020s, and this approval serves as a positive catalyst for the company’s growth roadmap.

Boehringer Ingelheim Perspective

Boehringer Ingelheim anticipates that securing an early‑stage patient selection tool during drug development will increase the probability of clinical trial success and enable a differentiated therapeutic option at market launch. Faster market entry relative to competitors is expected to expand market share and drive revenue growth.